Volume 387, Issue 10038, Pages 2622-2629 (June 2016) Hysteroscopy before in-vitro fertilisation (inSIGHT): a multicentre, randomised controlled trial Janine G Smit, MD, Jenneke C Kasius, PhD, Prof Marinus J C Eijkemans, PhD, Carolien A M Koks, PhD, Ronald van Golde, PhD, Annemiek W Nap, PhD, Gabrielle J Scheffer, PhD, Petra A P Manger, PhD, Annemieke Hoek, PhD, Benedictus C Schoot, PhD, Arne M van Heusden, PhD, Walter K H Kuchenbecker, PhD, Denise A M Perquin, PhD, Kathrin Fleischer, PhD, Eugenie M Kaaijk, PhD, Alexander Sluijmer, PhD, Jaap Friederich, PhD, Ramon H M Dykgraaf, Marcel van Hooff, PhD, Leonie A Louwe, MD, Janet Kwee, PhD, Corry H de Koning, Ineke C A H Janssen, PhD, Femke Mol, PhD, Prof Ben W J Mol, PhD, Prof Frank J M Broekmans, PhD, Helen L Torrance, PhD The Lancet Volume 387, Issue 10038, Pages 2622-2629 (June 2016) DOI: 10.1016/S0140-6736(16)00231-2 Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile IVF=in-vitro fertilisation. *Not known at randomisation. The Lancet 2016 387, 2622-2629DOI: (10.1016/S0140-6736(16)00231-2) Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 2 Time to pregnancy (positive pregnancy test) leading to livebirth Participants with incomplete follow-up were deemed to be not pregnant at 18 months of follow-up. IVF=in-vitro fertilisation. HR=hazard ratio. The Lancet 2016 387, 2622-2629DOI: (10.1016/S0140-6736(16)00231-2) Copyright © 2016 Elsevier Ltd Terms and Conditions